Who Paid My Doc
Paul Miller
Reproductive Endocrinology Greenville, SC Medical Doctor
NPI 1194772475 CMS profile 144606
890 W Faris Rd, Suite 470, Greenville, SC 29605
General payments
$173,884
Research payments
$5,249
Ownership & investment interest
$0
Research they led as principal investigator
$295,258
Through program year 2025, Paul Miller of Greenville, SC is reported in the CMS Open Payments database as having received $173,884 across 228 general payments and $5,249 in research payments paid to them. Separately, studies naming them as principal investigator received $295,258 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 99th percentile of Reproductive Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
9 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $55 | 2 | |
| 2024 | General | $34 | 2 | |
| 2023 | General | $119 | 6 | |
| 2022 | General | $2,808 | 13 | |
| 2021 | General | $8,084 | 26 | |
| 2020 | General | $46,907 | 49 | |
| 2020 | Research | $3,898 | 1 | |
| 2019 | General | $115,877 | 130 | |
| 2019 | Research | $1,351 | 1 |
Beside peers
- Paul Miller
- Reproductive Endocrinology median
- Middle half of Reproductive Endocrinology
- National median
In program year 2025, general payments to Paul Miller were reported at $55. Among 986 Reproductive Endocrinology profiles paid that year, the median was $141 and the middle half received between $66 and $285.
Show as a table
| Year | Paul Miller | Reproductive Endocrinology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $115,877 | $196 | $77–$425 | $163 |
| 2020 | $46,907 | $81 | $35–$182 | $114 |
| 2021 | $8,084 | $102 | $43–$247 | $132 |
| 2022 | $2,808 | $139 | $62–$303 | $149 |
| 2023 | $119 | $141 | $65–$285 | $160 |
| 2024 | $34 | $144 | $65–$302 | $164 |
| 2025 | $55 | $141 | $66–$285 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 10 drugsPart D claims
206
Drug cost
$8,623
Branded share of claims
52.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Estradiol (Twice Weekly) Estradiol | Brand | 35 | $3,142 | |
| Zafemy Norelgestromin/Ethin.Estradiol | Brand | 17 | $1,489 | |
| Armour Thyroid Thyroid,pork | Brand | 18 | $1,175 | |
| Hydrocortisone | Generic | 18 | $771 | |
| Progesterone Progesterone, Micronized | Brand | 38 | $725 | |
| Estradiol | Generic | 23 | $677 | |
| Norethindrone Acetate | Generic | 15 | $416 | |
| Levothyroxine Sodium | Generic | 19 | $132 | |
| Alprazolam | Generic | 12 | $82 | |
| Zolpidem Tartrate | Generic | 11 | $15 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 6,527 Part D prescribers listed as Endocrinology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 10 billing codesPaid by Medicare
$2,636
Medicare patients
23
Services billed
89
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Arthritis | 48% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
230 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Reproductive Endocrinology in South Carolina
Travis McCoy
Reproductive Endocrinology · Greenville, SC
Jeris Cox
Reproductive Endocrinology · Mount Pleasant, SC
Creigton Likes
Reproductive Endocrinology · Greenville, SC
John Payne
Reproductive Endocrinology · Greenville, SC
Jessica McLaughlin
Reproductive Endocrinology · Charleston, SC
John Schnorr
Reproductive Endocrinology · Mt. Pleasant, SC
Related records
Reproductive Endocrinology in South Carolina
Practitioners in the same specialty and state, ranked by reported value.
All Reproductive Endocrinology
Everyone recorded under this specialty, nationwide.
Doctors in South Carolina
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.